Sophia Genetics Reports Q2 Revenue Up 27 Percent, CDx Deal with AstraZeneca
The multi-year collaboration with AstraZeneca aims to develop two companion a solid tumor test and a blood cancer test.
Sophia Genetics said on Aug. 4 that its second quarter revenue rose 27 percent year over year.
Alongside its earnings, Sophia announced its first-ever companion diagnostic collaboration, a multi-year agreement with AstraZeneca to develop and validate two programs. “For the first CDx program, we will develop our solid tumor application into a decentralized companion diagnostic,” CEO Ross Muken said on a call with investors following the release of results. “The second CDx program will leverage our hematological oncology application to support a therapy for patients with blood cancer. Financial and other details were not disclosed.
“These programs will not only provide a meaningful revenue accelerator for years to come, but they will also provide a foundation to collect even more data about the patient, build real-world evidence assets and develop new and unique clinical intelligence tools,” he said. “And with these two wins, we are just getting started.”
The Switzerland-based precision medicine company reported Q2 revenue of $23.3 million, up from $18.3 million in Q2 2025, driven by a 60 percent increase in US test analysis volume, 80 percent revenue growth in liquid biopsy analysis, and accelerating biopharma revenue. The company performed a record 115,000 analyses on its platform during the quarter, up 22 percent year over year, and ended the period with 542 core genomics customers, up from 490 a year ago.
The company’s net loss for the quarter was $22.4 million, or $.30 per share, compared to a loss of $22.4 million, or $.33 per share, in Q2 2025.
Sophia raised its full-year 2026 revenue guidance to $94 million to $96 million, representing growth of 22 to 24 percent, from a prior range of $92 million to $94 million.
R&D expenses were $8.7 million in Q2 2026, up from $8.5 million a year ago. SG&A expenses rose 18 percent year over year to $26.4 million from $22.3 million.
The company completed a $57.5 million public offering during the quarter, bringing cash and cash equivalents to $107.7 million as of June 30.